IBI Lorenzini at the forefront against the counterfeiting of drugs

26 September 2017

Milan, 26 September 2017 – Tracing drugs through serial numbers to allow the identification of stolen or counterfeited products: IBI Lorenzini raises to the challenge to fight the pharmaceutical product counterfeiting market, one of the most serious threats to public health, and does it well in advance of the EU Regulation, which will enter into force in 2019, by implementing digital counter-measures for the reduction of risks. It’s the Rockwell Automation Pharma Suite software the electronic “key” that will guarantee safety, control and transparency for IBI products.

The pharmaceutical company of Aprilia, driven by Camilla Borghese Khevenhüller, at the forefront of the Industry 4.0 project, has introduced today in Milan, during an event dedicated to industrial automation (at the premises of Tecniche Nuove) the innovative strategies implemented in its production lines, giving particular attention to those relating to traceability, and the implementation of the Rockwell Automation software.

The whole European pharmaceutical sector will in fact soon have to accept the new challenge posed by EU Regulation 2011/62, which defines the drug control procedures for the reduction of counterfeiting threats. The new dispositions are part of a path initiated in 2013 by the USA market, when the then president Barack Obama signed the DSCSA (Drug Supply Chain Security Act). The achieving of these objectives requires the implementation of innovative electronic systems for the safe identification and tracking of drug prescription and distribution, and is the basis for the choice made by IBI.

“The track-and-trace” system”, explained during the event in Milan Luca Pezzano, Operational Director of IBI “greatly increases the safety of the drug production process. It guarantees in fact a higher level of transparency and responsibility in production, improves logistic exchanges and allows the identification of stolen and counterfeited products. The serial numbers are fundamental for managing the whole distribution process, ensuring complete traceability. For this reason”, he concludes “the serial number is printed on each sale unit, on each box containing single units and on each pallet where the boxes are stacked.”

The Industry 4.0 revolution is reaching all company sectors, and it was unavoidable that it would also affect such delicate fields for public health as the healthcare and pharmaceutical sectors. Total drug traceability is one of the main objectives of this digital revolution: for the USA market, the obligation for manufacturers starts from November 2017 and the project will be completed in 2023. On the other hand, as far as Europe its realisation should be completed by February 2019, while in Italy the limit is February 2025. IBI Lorenzini is therefore at the forefront in applying a change that in future years will be mandatory for all the companies of the sector.

IBI Lorenzini
IBI Lorenzini
IBI Lorenzini
IBI Lorenzini

Latest news


Seguiamo i farmaci fino a voi

Cinquanta milioni di investimento digitale e un forte impegno nella tracciabilità dei prodotti

Read all

Industry Experts Combine to Create Safer Intravenous Delivery

The Italian Biochemical Institute, Comecer, and Particle Measuring Systems share expertise to develop and manufacture a safer intravenous solution.

Read all

Camilla Borghese, the princess in white coat in charge of pharmaceutical Ibi

Read all

Thank you

We sent you an email. To activate the newsletter click on the link you will find in the message, thank you!


Private area

Log in to restricted area


Notice on the treatment of personal data

Dear visitor, in the following sections we will describe how the reserved area of the website is managed as far as processing personal data of users. The notice is issued pursuant to art. 13 of EU Regulation 679/2016 (hereinafter also the Regulation) on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and applies to those who interact with the website of Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (hereinafter I.B.I.), which can be accessed at the following address:, the opening page of the official I.B.I. website. The notice only applies to the I.B.I. website. It does not apply to any other websites that the user may access through links.

  1. The processing of the personal data that you supply, which are also used for the creation of your user profile, and which will be included in the “Doctors’ Details” database, has the following purposes:
  • carry out medical sales related activities for drugs for human consumption. Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. and Ibigen S.r.l., part of the same company group (hereinafter also Ibigen Group), carry out such activities in compliance with the provisions of the current regulations, with particular, but not exclusive, attention to Italian Legislative Decree no. 219 of 24.04.2006 and subsequent modifications. In view of the objectives of the Ibigen Group, it is important to point out that the processing activities do not deal with any special data. The supply of the data for the medical sales activities is necessary, and failure to provide consent will make it impossible for us to fulfil the above objectives;

  • forwarding of invitations or information on congresses, conferences, seminars, communications on initiatives promoted or sponsored by the Ibigen group, regular or occasional publications, information on new products, methods and services. Such activities are carried out by e-mail, fax, SMS, normal post or telephone. The supply of the data for such purposes is optional, and failure to supply them will result in the information not being forwarded.

  1. As far as the creation of your profile on our website, we remind you that your password is strictly confidential and should not be disclosed.
  2. Your data will not be disclosed, but may be shared with individuals, companies, associations or professional studios providing support or consultancy services to the Ibigen Group, the medical sales representative network, our suppliers and any sub-suppliers - from time to time entrusted with activities connected with the above objectives -, mailing or statistical survey companies, or companies for the forwarding of scientific documentation, and individuals authorised to access the data by law and/or pursuant to secondary regulations.
  3. Such people may only acquire knowledge of your personal data for the above mentioned purposes.
  4. The Owners of the Treatment (Data Controllers) are the two companies of the Ibigen Group with legal headquarters at Via Fossignano no. 2, Aprilia (LT), Italy.
  5. Personal data are processed using manual and automated means, for the time necessary for reaching the objectives for which they were collected. Special safety measures are in place to avoid data loss, unlawful or incorrect use and unauthorised access.
  6. Lastly, we also inform you that you can at any time exercise the rights contemplated by the Regulation, and in particular request access to the data, their correction, update and block, or you can withdraw your consent, or request the limitation of the processing or the cancellation of the data. As data subject, you also have the right to issue a complaint with the relevant control Authority. Such rights may be exercised in writing to the following e-mail address:
  7. The Data Protection Officer may be contacted at the following e-mail address:

* Required fields